Online ISSN: 1945-4589
Mission
Aging's mission is to share novel scientific discoveries across all fields of age-related research. We welcome scientists from all disciplines, not only those in traditional gerontology. We aim to spread knowledge of the mechanisms surrounding aging and age-related disease, and ultimately seek to understand how to modulate these pathways to extend healthy life.

Launched in 2009, Aging is a peer-reviewed, traditional-style, monthly journal with free access.

As a traditional journal, Aging publishes papers online in monthly issues with page numbers. Each issue/paper can be printed upon special request.

Accepted papers appear online and in PubMed very quickly.

Aging is indexed in PubMed/Medline (abbreviated as Aging (Albany NY), PubMed Central (abbreviated as Aging (Albany NY), Web of Science/Science Citation Index Expanded (abbreviated as Aging-US), Scopus (abbreviated as Aging), BIOSIS Previews, Biological Abstracts, and EMBASE. In 2018, Aging was invited to participate and will be indexed in META, a world-renowned database of scientific literature. All Aging content is archived in PubMed Central.

The publisher also maintains the journal's own digital archive.

IMPACT FACTOR
(IF) WEB OF SCIENCE
2017 5-YR IMPACT FACTOR 5.437
2017
2016
2015
2014
2013
2012
2011
-
-
-
-
-
-
-
5.179
4.867
3.979
6.432
4.886
4.696
5.127

Aging publishes high-impact research papers of general interest and biological significance in all fields of aging research, including, but not limited to, cellular senescence, DNA damage and repair, organismal aging, age-related diseases, genetic control of aging from yeast to mammals, regulation of longevity, evolution of aging, anti-aging strategies and drug development, and especially the role of signal transduction pathways in aging and potential approaches to modulate these signaling pathways to extend lifespan.

Aging also covers many other topics (beyond traditional gerontology), including cellular and molecular biology (e.g., regulation of translation, cell growth, death and autophagy, mitochondria, microRNAs, and stem cells), human age-related diseases, pathology in model organisms, cancer and signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR among others), and approaches to modulate these signaling pathways.

ARCHIVING & INDEXING
  • PubMed/Medline (abbreviated as "Aging (Albany NY)")
  • PubMed Central (abbreviated as "Aging (Albany NY)")
  • Web of Science/Science Citation Index Expanded (abbreviated as Aging-US) & listed in the Cell Biology-SCIE and Geriatrics & Gerontology category
  • Scopus /Rank Q1(the highest rank) (abbreviated as Aging)- Aging and Cell Biology category
  • Biological Abstracts
  • BIOSIS Previews
  • EMBASE
  • META (Chan Zuckerberg Initiative)

The Aging Editorial Board is composed of scientists from all over the world, predominantly from the USA. Among them are Cynthia Kenyon, Judith Campisi, Leonard Guarente, Michael Hall, Thomas Rando, and other outstanding scientists. The Board includes six members of the National Academy of Sciences (USA) and Lasker and Nobel Award recipients (Elizabeth H. Blackburn). It also includes the directors of some of the largest American cancer centers, directors of research from prominent pharmaceutical companies, professors from prestigious Universities, Editors of leading journals, and other prolific and distinguished scientists.

Aging has published outstanding papers and reviews by Lawrence Donehower, Toren Finkel, Stephen Helfand, Gerald Shadel, Andre Nussenzweig, Maurice Burg, Karen Vousden, Leonard Guarente, Dale Bredesen and other highly cited authors.

Elizabeth Blackburn, a member of the Editorial Board of Aging, won the Nobel Prize in Physiology or Medicine 2009 while a member of the Board. Elizabeth Blackburn co-authored a paper published in the inaugural issue of Aging.

Andrew V. Schally, a Nobel Prize Laureate, published a paper in Aging.

Shinya Yamanaka, who won the Nobel Prize in Physiology and Medicine 2012, has co-authored a paper published in Aging.

Aging is now offering free Altmetric Article Reports as a new part of our Journal platform, which enables real-time tracking of article coverage in digital and traditional media channels, often long before traditional citations begin to accrue.

We are pleased to announce the new face of Aging coming in 2018 with an enhanced content delivery platform, new features, and intuitive navigation.

Aging follows the COPE guidelines and ICMJE's Recommendations

Our mission is to share novel scientific discoveries across all fields of age-related research. We welcome scientists from all disciplines, not only those in traditional gerontology. We aim to spread knowledge of the mechanisms surrounding aging and age-related disease, and ultimately seek to understand how to affect these pathways to extend healthy life.

Join our Aging mailing list

Online ISSN: 2331-4737
Mission
Oncoscience's mission is to cover the rapidly growing field of cancer research. We aim to focus on emergent topics not currently covered by other journals.

Oncoscience has also a special mission: freeing researchers in oncology from publication costs. It is free for both readers and authors.

Launched in 2014, Oncoscience is a peer-reviewed, traditional-style, bi-monthly journal with free access. Oncoscience also has a special mission: freeing researchers in oncology from publication costs. It is free for both readers and authors.

As a traditional journal, Oncoscience publishes papers online in issues with page numbers. Each issue/paper can be printed upon special request.

All Oncoscience content is archived in PubMed Central.

The publisher also maintains the journal's own digital archive.

Oncoscience is indexed/abstracted in PubMed, PubMed Central, Scopus (Oncology category), and EMBASE. In 2018, Oncoscience was invited to participate and will be indexed in META, a world-renowned database of scientific literature.

ARCHIVING & INDEXING
  • PubMed
  • PubMed Central
  • Scopus (Oncology category)
  • EMBASE
  • META (Chan Zuckerberg Initiative)

Oncoscience covers the rapidly growing field of cancer research, especially emergent topics not currently covered by other journals. Cancer research has entered a new phase in which the convergence of information from different disciplines (e.g., cancer biology, bioinformatics, chemistry, and drug design among others) is beginning to provide new insight into tumor development and cancer treatment.

To capture the key elements of this phase, Oncoscience covers all aspects of the structure and function of oncogenes, growth suppressor and apoptotic genes, as well as their role in signal transduction and the mechanisms by which their expression and function are altered during tumor development. In addition to publishing manuscripts that directly relate to these areas of research, the journal covers the niche of interdisciplinary articles that bring together cancer biology, chemistry, and drug design.

Oncoscience also regularly publishes Editorials on emergent topics and commentaries on highly visible papers published in other journals.

Its international Editorial Board includes 65 members from different countries, including the USA (predominantly), United Kingdom, Sweden, France, Denmark and Spain. All are highly cited authors, professors at leading universities, and are supported by numerous NIH grants. The Editorial Board includes 20 members of the National Academy of Sciences (USA), 6 Lasker Award recipients (Brian Druker, Andrew Schally, Alexander Varshavsky, Stephen J. Elledge, William G. Kaelin,Jr., and Greg L. Semenza) and a Nobel Prize winner (Andrew Schally).

Our authors are from more than 25 countries on different continents.

Oncoscience is now offering free Altmetric Article Reports as a new part of our Journal platform, which enables real-time tracking of article coverage in digital and traditional media channels, often long before traditional citations begin to accrue.

We are pleased to announce the new face of Oncoscience coming in 2018 with an enhanced content delivery platform, new features, and intuitive navigation.

Oncoscience always follows the COPE guidelines and ICMJE's Recommendations

Join our Oncoscience mailing list

Online ISSN: 1947-6027
Mission
Genes & Cancer's mission is to combine research from the fields of genomics, bioinformatics, and modem genetics to determine how cancer cells overcome growth regulatory pathways. We aim to cover all aspects of oncogenes, growth suppressor and apoptotic genes, and their roles in tumor development.
Genes & Cancer (formerly a SAGE publication) was acquired in 2014. It is a traditional, peer-reviewed, bi-monthly journal with free access.

As a traditional journal, Genes & Cancer publishes papers online in issues with page numbers. Each issue/paper can be printed upon special request.

Advance papers are usually published online several days after acceptance. All Genes & Cancer content is archived in PubMed Central.

The publisher also maintains the journal's own digital archive.

ARCHIVING & INDEXING
  • PubMed
  • PubMed Central
  • Scopus/Q1 rank (the highest) - Cancer Research category
  • EMBASE
  • META (Chan Zuckerberg Initiative)

The journal covers all aspects of the structure and function of oncogenes, growth suppressor and apoptotic genes, as well as their role in signal transduction and the mechanisms by which their expression and function are altered during tumor development. Genes & Cancer aims to capture the excitement of new phases of cancer research through genomics, bioinformatics and modern genetics.

Genes & Cancer is indexed/abstracted in PubMed, PubMed Central, Scopus (Cancer Research category, Q1 rank), and EMBASE. In 2018, Genes & Cancer was invited to participate and will be indexed in META, a world-renowned database of scientific literature.

Genes & Cancer is now offering free Altmetric Article Reports as a new part of our Journal platform, which enables real-time tracking of article coverage in digital and traditional media channels, often long before traditional citations begin to accrue.

We are pleased to announce the new face of Genes & Cancer coming in 2018 with an enhanced content delivery platform, new features and intuitive navigation.

Genes & Cancer always follows the COPE guidelines and ICMJE's Recommendations

Genes & Cancer is a member of the Committee on Publication Ethics (COPE)

Join our Genes mailing list

Online ISSN: 1949-2553
Aims and Scope

Oncotarget aims to maximize research impact through insightful peer-review, eliminate borders between specialties by linking different fields of biomedical science, and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types and even tissues that can be viewed as targets relevant to cancer and other diseases as well. The term was introduced in the inaugural Editorial Introducing OncoTarget, https://doi.org/10.18632/oncotarget.101.

Launched in 2010, Oncotarget is a peer-reviewed, traditional-style journal with free access.

As a traditional journal, Oncotarget publishes papers online in issues with page numbers. Since August 2017, Oncotarget has published two issues per week: on Tuesday and Friday. Final paginated issues are released to PubMed quickly and in their permanent form. Each issue/paper can be printed upon special demand.

Currently, more than 20,000 Oncotarget papers are searchable on PubMed.

Oncotarget is indexed in PubMed, PubMed Central, Web of Science/Science Citation Index Expanded (2010-2017), Scopus, and EMBASE. In 2018, Oncotarget was invited to participate and is now indexed in META, a world-renowned database of scientific literature. In all Indexes, the Journal's abbreviation is Oncotarget.

According to Web of Science, Oncotarget's Impact Factor (IF 2016) is 5.168, and its 5-year IF (2016) is 5.415.

IMPACT FACTOR
(IF) WEB OF SCIENCE
2016 5-YR IMPACT FACTOR 5.415
2016
2015
2014
2013
2012
2011
-
-
-
-
-
-
5.168
5.008
6.359
6.627
6.636
4.784

Also, according to Web of Science, Oncotarget's 2016 Normalized Eigenfactor is 9.02 (the average Eigenfactor is 1 by definition), demonstrating the importance of the journal for the field.Scopus/SJR ranking: 2011-ongoing: Q1 (highest rank). All years Q1 in Medicine and Oncology category. According to Scopus, Oncotarget ranks number 1 on Total Documents (2015-2016) among all journals in Oncology. All Oncotarget content is archived in PubMed Central.

The publisher also maintains the journal's own digital archive.

The founding Editors include Nobel Prize winner Andrew V. Schally; Lasker Award recipients Alexander Varshavsky, Brian J. Druker, Gregg L. Semenza, and William G. Kaelin, Jr.; and 12 Members of the US National Academy of Sciences.

ARCHIVING & INDEXING
  • PubMed
  • PubMed Central
  • ISI / Web of Science: Science Citation Index Expanded (2010-2017)
  • Scopus
  • EMBASE
  • META (Chan Zuckerberg Initiative)

Oncotarget has published outstanding papers and reviews by Bert Vogelstein, Peter K. Vogt, Pier Paolo Pandolfi, Arnold J. Levine, Brian Druker, Carol Prives and other outstanding scientists.

Oncotarget is now offering free Altmetric Article Reports as a new part of our journal platform, which enables real-time tracking of article coverage in digital and traditional media channels, often long before traditional citations begin to accrue.

We are pleased to announce the new face of Oncotarget coming in 2019 with an enhanced content delivery platform, new features, and intuitive navigation.

Join our Oncotarget mailing list